Barrier Effect of Normal Microbiota Against Clostridium difficile may be Influenced by Drugs Devoid of Antibiotic Activity

References

• Barc MC, Depitre C, Gorthier G, Collignon A, Su WJ, Bourlioux P. Effects of antibiotics and other drugs on toxin production in Clostridium difficile in vitro, in vivo. Antimicrobial Agents and Chemotherapy 1992; 6: 1332–1335
   Google Scholar
• Bartlett JG. Treatment of antibiotic associated pseudomembranous colitis. Reviews of Infectious Diseases 1984; 6: 235–241
   PubMedGoogle Scholar
• Bartlett JG. Antimicrobial agents implicated in Clostridium difficile toxin associated diarrhoea or colitis. Johns Hopkins Medical Journal 1981; 147: 4–9
   Google Scholar
• Boriello SP, Ketley JM, Mitchell TJ, Barclay FE, Welch AR, Price AB, Stephen NJ. Clostridium difficile: a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis. Journal of Medical Microbiology 1987; 24: 53–64
   Web of Science ®Google Scholar
• Brunetto AL, Pearson ADJ, Craft AW, Pedler SJ. Clostridium difficile in an oncology unit. Archives of Diseases of Children 1988; 63: 979–981
   PubMed Web of Science ®Google Scholar
• Church JM, Fazio VW. A role for colonic stasis in the pathogenesis of disease related to Clostridium difficile. Diseases of Colon and Rectum 1986; 29: 804–809
   Web of Science ®Google Scholar
• Collignon A, Chaumard C, Vallet-Collomb I, Delepine N. Clostridium difficile chez des enfants et adolescents sous chimiothérapie anti-cancéreuse et antiinfectieuse; Possibilité d'une acquisition nosocomiale. Pathologie et Biologie 1988; 36: 755–758
   Google Scholar
• Corthier G, Dubos F, Raibaud P. Modulation of cytotoxin production by Clostridium difficile in the intestinal tract of gnotobiotic mice inoculated with various human intestinal bacteria. Applied and Environmental Microbiology 1985; 49: 250–252
   PubMed Web of Science ®Google Scholar
• Corthier G, Muller MC, Wilkins TD, Lyerly D, L'Haridon R. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infection and Immunity 1991; 59: 1192–1195
   PubMed Web of Science ®Google Scholar
• Cudmore MA, Silva J, Fekety R, Liepmann MK, Kim KH. Clostridium difficile colitis associated with cancer chemotherapy. Archives of Internal Medicine 1982; 142: 333–335
   Google Scholar
• Cundy T, Trafford JAP, Thorn BT, Somerville PG. Clostridium difficile and non-antibiotic-associated colitis. Lancet 1980; 2: 595
   Web of Science ®Google Scholar
• Fainstein V, Bodey GP. Relapsing pseudomembranous colitis associated with cancer chemotherapy. Journal of Infectious Diseases 1981; 143: 865
   PubMed Web of Science ®Google Scholar
• George RH, Johnson M, Youngs D, Burdon DW (1979) Induction of Clostridium difficile toxin by antibiotics. Proceedings of 11th International Congress of Chemotherapy and 19th Interscience. 1979, 955–956
   Google Scholar
• Gerard MN, Defresne P, Daneau P, van der Auwera P, Delmee M, Bourguignon AM, Meunie F. Incidence and significance of Clostridium difficile in hospitalized cancer patients. European Journal of Clinical Microbiology and Infectious Diseases 1988; 1: 274–278
   Google Scholar
• Hartley JW. Clostridium difficile in an oncology unit. Archives of Diseases of Children 1989; 64: 765
   Web of Science ®Google Scholar
• Heard SR, O'Farell S, Crook D, Barnett MJ, Tabaqchali S. The epidemiology of Clostridium difficile with use of a typing scheme: nosocomial acquisition and cross-infection among immunocompromised patients. Journal of Infectious Diseases 1986; 153: 159–162
   Web of Science ®Google Scholar
• Honda T, Hernadez I, Katoh T, Miwatani T. Stimulation of enterotoxin production of Clostridium difficile by antibiotics. Lancet 1983; 1: 655
   PubMed Web of Science ®Google Scholar
• Larson HE, Levi AJ, Borriello SP. Vanco-mycin for pseudomembranous colitis. Lancet 1978; 2: 48
   Web of Science ®Google Scholar
• Libby JM, Donta ST, Wilkins TD. Clostridium difficile toxin A in infants. Journal of Infectious Diseases 1983; 148: 606
   PubMed Web of Science ®Google Scholar
• Lyerly DM, Krivan HC, Wilkins TD. Clostridium difficile: its disease and toxins. Clinical Microbiological Reviews 1988; 1: 1–18
   PubMedGoogle Scholar
• Lyerly DM, Phelps CJ, Wilkins TD. Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A. Journal of Clinical Microbiology 1985; 21: 12–14
   PubMed Web of Science ®Google Scholar
• Lyerly DK, Saum E, MacDonald D, Wilkins TD. Effects of Clostridium difficile toxins given intragastrically to animals. Infection and Immunity 1985; 47: 349–352
   PubMed Web of Science ®Google Scholar
• Mahe SG, Gorthier G, Dubos F. Effect of various diets on toxin production by two strains of Clostridium difficile in gnotobiotic mice. Infection and Immunity 1987; 55: 1801–1805
   PubMed Web of Science ®Google Scholar
• Maniar AC, Williams TW, Hammond GW. Detection of Clostridium difficile toxin in various tissue culture monolayers. Journal of Clinical Microbiology 1987; 25: 1999–2000
   Web of Science ®Google Scholar
• Miller SD, Koornhof HJ. Clostridium difficile colitis associated with the use antineoplastic agents. European Journal of Clinical Microbiology and Infectious Diseases 1984; 3: 10–13
   Web of Science ®Google Scholar
• Morris JG, Jarvis WR, Nunez-Montiel OL, Towns M, Thompson FS, Dowel VR, Hill EO, Vogle WR, Winton E, Hughes JM. Colonization and toxin production disorders in a cohort of patients with malignant hematologic disorders. Archives of Internal Medicine 1984; 144: 967–969
   PubMed Web of Science ®Google Scholar
• Pierce PF, Wilson R, Silva J, Garagusi VF, Rifkin GD, Fekety R, Nunez-Montiel O, Dowel VR, Hughes JM. Antibiotic associated pseudomembranous colitis: an epidemiologic investigation of cluster of cases. Journal of Infectious Diseases 1982; 145: 269–274
   PubMed Web of Science ®Google Scholar
• Pothoulakis CR, Sullivan R, Melnick DA, Triada-Filopoulos G, Gardienne AS, Meshulam T, Lamont JT. Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. Journal of Clinical Investigation 1988; 81: 1741–1745
   Web of Science ®Google Scholar
• Rambaud JC, Marteau P, Sobhani I, Beretta I. Pathophysiology of C. difficile-related disease. Microbial Ecology and Intestinal Infections, Bergogne-Berezin. Springer-Verlag, Berlin 1988; 57–72
   Google Scholar
• Rampling A, Warren RE, Bevan PC, Hoggarth CE, Swirsky D, Haynoe FGJ. Clostridium difficile in haematological malignancy. Journal of Clinical Pathology 1985; 38: 445–451
   PubMed Web of Science ®Google Scholar
• Saquet EP, Raibaud P, Gamier J. Etude comparée de la microflore de l'estomac, de l'intestin grěle et du caecum du rat holoxénique. Annales Institut Pasteur 1971; 120: 501–524
   Google Scholar
• Silva JR, Fekety R, Werk C, Erbright J, Cudmore M, Batts D, Syrjamak C, Lukens J. Inciting and etiologic agents of colitis. Reviews of Infectious Diseases 1984; 6: s214–s221
   PubMedGoogle Scholar
• Talbot RW, Walker RC, Beart RW. Changing epidemiology, diagnosis and treatment of Clostridium difficile toxin associated colitis. British Journal of Surgery 1984; 73: 457–460
   Web of Science ®Google Scholar
• Taylor SG, Hass GM, Crumrine JL, Slaughter DP. Toxic reactions of 4-aminopteroyl-glutamic acid (aminopterin) in patients with far advanced neoplastic disease. Cancer 1950; 3: 493–503
   PubMed Web of Science ®Google Scholar
• Tedesco TJ. Clindamycin colitis: a review. Journal of Infectious Diseases 1977; 135: s95–s98
   PubMed Web of Science ®Google Scholar
• Wilkins TD. Role of Clostridium difficile toxins in disease. Gastroenterology 1977; 93: 389–391
   Google Scholar